MX2023013093A - Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida. - Google Patents
Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida.Info
- Publication number
- MX2023013093A MX2023013093A MX2023013093A MX2023013093A MX2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A
- Authority
- MX
- Mexico
- Prior art keywords
- free base
- crystalline forms
- phenylfuro
- phenylethylamino
- enamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218504P | 2021-07-06 | 2021-07-06 | |
| PCT/US2022/036260 WO2023283269A1 (en) | 2021-07-06 | 2022-07-06 | Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013093A true MX2023013093A (es) | 2024-04-09 |
Family
ID=84802010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013093A MX2023013093A (es) | 2021-07-06 | 2022-07-06 | Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12240858B2 (enExample) |
| EP (1) | EP4330259A4 (enExample) |
| JP (1) | JP7565118B2 (enExample) |
| KR (1) | KR102783648B1 (enExample) |
| CN (1) | CN116916922B (enExample) |
| AU (1) | AU2022307875B2 (enExample) |
| BR (1) | BR112023024853A2 (enExample) |
| CA (1) | CA3217088A1 (enExample) |
| IL (1) | IL308946B2 (enExample) |
| MX (1) | MX2023013093A (enExample) |
| TW (1) | TWI809967B (enExample) |
| WO (1) | WO2023283269A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI906763B (zh) * | 2024-02-05 | 2025-12-01 | 財團法人國家衛生研究院 | 表皮生長因子受體抑制劑 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507502B2 (en) * | 2008-11-10 | 2013-08-13 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| KR101301533B1 (ko) * | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
-
2022
- 2022-07-05 TW TW111125153A patent/TWI809967B/zh active
- 2022-07-06 JP JP2023544357A patent/JP7565118B2/ja active Active
- 2022-07-06 CA CA3217088A patent/CA3217088A1/en active Pending
- 2022-07-06 BR BR112023024853A patent/BR112023024853A2/pt unknown
- 2022-07-06 CN CN202280009812.5A patent/CN116916922B/zh active Active
- 2022-07-06 IL IL308946A patent/IL308946B2/en unknown
- 2022-07-06 WO PCT/US2022/036260 patent/WO2023283269A1/en not_active Ceased
- 2022-07-06 AU AU2022307875A patent/AU2022307875B2/en active Active
- 2022-07-06 KR KR1020237023847A patent/KR102783648B1/ko active Active
- 2022-07-06 MX MX2023013093A patent/MX2023013093A/es unknown
- 2022-07-06 US US17/858,321 patent/US12240858B2/en active Active
- 2022-07-06 EP EP22838355.0A patent/EP4330259A4/en active Pending
-
2024
- 2024-07-17 US US18/775,916 patent/US20240368175A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW202309041A (zh) | 2023-03-01 |
| JP2024514995A (ja) | 2024-04-04 |
| US12240858B2 (en) | 2025-03-04 |
| IL308946A (en) | 2024-01-01 |
| KR102783648B1 (ko) | 2025-03-18 |
| IL308946B2 (en) | 2026-01-01 |
| CA3217088A1 (en) | 2023-01-12 |
| BR112023024853A2 (pt) | 2024-02-15 |
| CN116916922A (zh) | 2023-10-20 |
| TWI809967B (zh) | 2023-07-21 |
| WO2023283269A1 (en) | 2023-01-12 |
| AU2022307875A1 (en) | 2023-11-02 |
| CN116916922B (zh) | 2026-01-02 |
| AU2022307875B2 (en) | 2024-08-01 |
| US20230021909A1 (en) | 2023-01-26 |
| EP4330259A4 (en) | 2024-10-09 |
| KR20230118963A (ko) | 2023-08-14 |
| EP4330259A1 (en) | 2024-03-06 |
| JP7565118B2 (ja) | 2024-10-10 |
| IL308946B1 (en) | 2025-09-01 |
| US20240368175A1 (en) | 2024-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2424240C2 (ru) | Антибактериальные производные пиперидина | |
| RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| JOP20250072A1 (ar) | المركبات ثلاثية الحلقات واستخداماتها | |
| ECSP109979A (es) | Preparación sólida que contiene alogliptina y clorhidrato de metformina | |
| PY1923494A (es) | Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| CL2011001658A1 (es) | Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor. | |
| AR038914A1 (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion para fabricar un medicamento | |
| CY1109880T1 (el) | ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| MX2023006854A (es) | Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma. | |
| HN2002000156A (es) | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. | |
| CL2019003619A1 (es) | Preparación sólida para administración oral. | |
| MX2022012898A (es) | Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta. | |
| UY30393A1 (es) | Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| AR110249A1 (es) | Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| MX2023008671A (es) | Composicion farmaceutica. | |
| UY30363A1 (es) | Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones | |
| MX2023013093A (es) | Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida. | |
| CR20240203A (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| UY28357A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos | |
| MX2025011781A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi |